Progression of IgA gammopathy to myeloma following infliximab treatment for pyoderma gangrenosum

Summary Pyoderma gangrenosum (PG) may be associated with inflammatory disorders and haematological conditions such as monoclonal gammopathy of uncertain significance (MGUS). We report the case of a 53‐year old man who had PG and MGUS. After treatment with infliximab for the PG, he developed myeloma....

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinical and experimental dermatology 2012-03, Vol.37 (2), p.146-148
Hauptverfasser:	Shareef, M. S., Munro, L. R., Owen, R. G., Highet, A. S.
Format:	Artikel
Sprache:	eng
Schlagworte:	Anti-Inflammatory Agents - adverse effects Antibodies, Monoclonal - adverse effects Biological and medical sciences Dermatology Disease Progression Hematologic and hematopoietic diseases Humans Hypergammaglobulinemia - complications Immunodeficiencies. Immunoglobulinopathies Immunoglobulin A Immunoglobulinopathies Immunopathology Infliximab Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis Male Medical sciences Middle Aged Multiple Myeloma - chemically induced Multiple Myeloma - pathology Precancerous Conditions - pathology Pyoderma Gangrenosum - drug therapy Skin involvement in other diseases. Miscellaneous. General aspects Tumor Necrosis Factor-alpha - antagonists & inhibitors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Summary Pyoderma gangrenosum (PG) may be associated with inflammatory disorders and haematological conditions such as monoclonal gammopathy of uncertain significance (MGUS). We report the case of a 53‐year old man who had PG and MGUS. After treatment with infliximab for the PG, he developed myeloma. The course of events in this case suggests that infliximab facilitated the progression from MGUS to myeloma.
ISSN:	0307-6938 1365-2230
DOI:	10.1111/j.1365-2230.2011.04219.x